Larimar Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Bala Cynwyd, PA
LRMR chart
What traders are saying about $LRMR
Latest postsLarimar Therapeutics, Inc. news
- Larimar Therapeutics, Inc. (LRMR) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Wedbush reiterates Larimar Therapeutics stock rating at Outperform By Investing.com
Investing.com South Africa ·
- Form 8K Larimar Therapeutics Inc For: 9 November By Investing.com
Investing.com Canada ·
- Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Yahoo Finance ·
- A treatment for Friedreich’s ataxia seeks FDA approval; children under 16 have no approved therapies
Stock Titan ·
- Larimar Therapeutics, Inc. (LRMR) Seasonal returns chart
Yahoo Finance UK ·
- Larimar Therapeutics Inc (ZA71.DU) Seasonal Returns Chart - Yahoo Finance
Yahoo! Finance Canada ·
- Larimar Therapeutics Inc (ZA71.DU) Seasonal returns chart
Yahoo Finance UK ·
- Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Yahoo Finance ·
- Larimar Therapeutics Announces Three Poster Presentations
GlobeNewswire ·
- Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Yahoo Finance ·
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
marketbeat.com ·
Larimar Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M |
| Diluted EPS | – | $-1.32 | $-0.84 | $-1.37 |
| Total assets (year end) | $145.8M | $200.2M | $95.9M | $126.4M |
| Cash and equivalents (year end) | $85.4M | $33.2M | $26.7M | $26.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Larimar Therapeutics, Inc.
- Ticker
- LRMR (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Bala Cynwyd, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1374690
- Former names
- ZAFGEN, INC., ZAFGEN INC
Frequently asked questions
What exchange is Larimar Therapeutics, Inc. listed on?
Larimar Therapeutics, Inc. trades on the Nasdaq under the ticker symbol LRMR.
What industry is Larimar Therapeutics, Inc. in?
Larimar Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Larimar Therapeutics, Inc. headquartered?
Larimar Therapeutics, Inc.'s business address on file with the SEC is in Bala Cynwyd, PA.
When does Larimar Therapeutics, Inc.'s fiscal year end?
Larimar Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Larimar Therapeutics, Inc. report?
Larimar Therapeutics, Inc. reported $0 in revenue for calendar year 2019, according to its SEC filings.